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Because of their high incidence andmortality solid cancers are amajor health problemworldwide.Although several newbiomarkers
and potential targets for therapy have been identified through biomolecular research in the last years, the effects on patients’
outcome are still unsatisfactory. Increasing evidence indicates that hERG1 potassium channels are overexpressed in human primary
cancers of different origin and several associations between hERG1 expression and clinicopathological features and/or outcome are
emerging. Aberrant hERG1 expression may be exploited either for early diagnosis (especially in those cancers where it is expressed
in the initial steps of tumor progression) or for therapy purposes. Indeed, hERG1 blockage impairs tumor cell growth both in vitro
and in vivo in preclinical mouse model. hERG1-based tumor therapy in humans, however, encounters the major hindrance of the
potential cardiotoxicity that many hERG1 blockers exert. In this review we focus on recent advances in translational research in
some of the most frequent human solid cancers (breast, endometrium, ovary, pancreas, esophagus, stomach, and colorectum) that
have been shown to express hERG1 and that are a major health problem.
1. Introduction
A biomarker is defined as a biological molecule indicating
atypical processes or disease that can be detected in tissues,
blood, and other body fluids. Biomarkers can be used to
evaluate the response to a particular treatment. In this view,
oncology research greatly relies on biomarkers for diagnostic,
prognostic, and predictive purposes.
In recent years, ion channels have been proven to be
expressed in different human cancers where they regulate
several cancer cell processes. In this view, ion channels could
represent novel cancer biomarkers, once properly validated
in the clinical setting.
Ion channels are pore-forming transmembrane proteins
that regulate passive ion fluxes that are important for key cell
processes (i.e., secretion, cell volume regulation). Ion chan-
nels are good potential markers because of their localization
at the plasmamembrane level.This factmakes their detection
(e.g., by immunohistochemistry (IHC)) easy and their block
with specific drugs and antibodies quick and tunable.
Among ion channels, those encoded by the ether-a`-go-
go related gene 1 (hERG1 also named KCNH2) are often
overexpressed in neoplastic cell lines and human primary
cancers of different histogenesis (reviewed in [1]). hERG1
belongs to an evolutionarily conserved multigenic family
of voltage-activated, outward rectifying K+ channels, the
EAG family. Physiologically, hERG1 channels are responsible
for the potassium current (𝐼Kr) that mediates the rapid
repolarizing phase following cardiac action potential.
The KCNH2 gene (formerly indicated as hERG1) was
cloned in 1994 from a human hippocampal cDNA library
and it is localized on chromosome 7, in q35-36 position [2].
hERG1 channel is composed of 1159 amino acids, and both
amino- and carboxy-terminals are located in the cytoplasm
(Figure 1).
Functional hERG1 channels are tetramers, and each
subunit is made of 6 transmembrane domains (S1–S6) and a
long loop which constitutes the pore. Once assembled in the
tetramers, the four loops contribute to form the aqueous pore
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Figure 1: Structure of hERG1 potassium channel. PAS: PAS (acro-
nym of Per Arnt Sim) domain; cNBD (cyclic nucleotide binding
domain).
in the center of the structure. The fourth transmembrane
segment (S4) contributes to form the voltage sensor domain
(VSD), which sharply contributes to hERG1 biophysical
properties [3].
In recent years, a progressively more defined picture is
emerging, in which hERG1 channels are expressed in several
types of human cancers [4] and regulate different cellular
processes [5–8]. hERG1 channels are overexpressed in human
primary cancers of different histogenesis such as endometrial
[9], colorectal [10], esophageal [11], and pancreatic [12]
adenocarcinomas and ovarian [13] and brain cancers [14] as
well as leukemias [15, 16].
It has been shown that hERG1 is not expressed by the
majority of normal nonexcitable tissues as well as hyperplas-
tic lesions (adenomas) [9–11]. Data gathered in the last 15
years underlined that hERG1 channels are important mod-
ulators of apoptosis [17] and cell proliferation in leukemias
[15, 16] and neuroblastomas [18]. However these tumors will
not be discussed in the present review and we refer to a more
focused review [19].
Cancers of the breast and reproductive system in females
and tumors of the gastrointestinal tract in both sexes col-
lectively represent a major health problem either for their
high incidence or poor outcome. Pieces of evidence have
been gathered that all the above-mentioned cancer types
express high levels of hERG1 channels. Table 1 summarizes
data gathered so far concerning hERG1 expression in cell lines
and in solid human cancers.
From an epidemiologic point of view the above-men-
tioned solid cancers (breast, endometrium, ovary, esophagus,
stomach, colorectum, and pancreas) represent a vast share
of both incidence and mortality for cancer worldwide [20]
(Figures 2(a) and 2(b)).
Five-year survival rates vary from 89.2% in women
affected by breast cancer to 81.5% in women suffering from
corpus uteri (endometrial) cancer and to 44.6% in women
with ovarian cancer; in both sexes, 5-year survival rates vary
from 64.7%, 28.3%, 17.5%, 16.8%, and 6.7% in patients with
colorectal, gastric, esophageal, lung, and pancreatic cancer,
respectively [21, 22].
The differences in survival are mainly represented by dis-
tinct biomolecular features as well as efficacy of prevention,
diagnostic accuracy, and response to treatment. Nowadays,
all these cancers require amultimodal approach that includes
oncologists, surgeons, and radiotherapists, although the con-
tribution of many other professionals is often of crucial
importance.
The purpose of this paper is to review the recent advances
in hERG1 research from cancers arising in breast, female
reproductive system, and digestive tract.
2. Breast Cancer
Breast cancer (BC) is the most common malignancy among
women worldwide and remains the primary cause of death
from cancer in females [36]. Unfortunately, BC incidence is
increasing everywhere and in less developed countries BC is
becoming a major health issue [36–38]. On the other hand,
mortality rates for BC are decreasing [36, 39] and it has been
estimated that lung cancer instead of BC will become the first
cause of death among women and in Europe in 2014, for the
first time [39].
A better knowledge of biological features, screening
protocols, and access to cutting edge therapies plays a key
role in BC treatment. Fisher [40] dramatically changed the
perception of BC, introducing the idea of a complex disease
from the very beginning of the pathogenetic process, with
different factors involved in the natural history of this cancer.
Nowadays, not only the TNM stage but also the biological
subtypes are crucial for BC clinical management. In order
to get a more accurate prognosis and prediction of therapy
benefits physicians should use accurate molecular technolo-
gies [41]. However, due to the high costs of such techniques,
surrogate definitions of subtypes (i.e., hormones expression,
proliferation index, andHER-2 expression) obtained through
IHC have become a valuable approach for clinicians [42].
The choice of endocrine therapy, chemotherapy regimens,
monoclonal antibodies, or kinase inhibitors is mostly driven
by the above biomarkers. A striking example of it is the
target therapy on HER-2 receptor employing the monoclonal
antibody Trastuzumab. Such treatment has significantly
changed survival rates in HER-2 positive BC [43]. Hormone-
responsive and HER-2 positive cancers are candidate of a
specific “biological therapy.” On the contrary, triple negative
cases, being devoid of any peculiar biomarker, can only be
treated with strong chemotherapy regimens. Moving down
this line, identification of biomarkers in BC is of utmost
clinical importance either as prognostic tools or as possible
therapeutic targets.
Ion channels could therefore represent novel biomarkers
in BC. Indeed several studies have already been published
addressing the expression of single ion channel types in BC.
More recently an ion channel molecular profile was defined
for BC, opening interesting perspectives in this field [44].
Long ago it was shown that hERG1 gene is expressed in
BC cell lines [4]. More recently, it was shown that hERG1
hyperstimulation in SKBR3 and MDA-MB-231 cells might
induce cell senescence [24]. In particular, the authors showed
that the exposure to hERG1 channel agonist (NS1643) causes
the cell cycle arrest inG0/G1 and induces cell senescence [24].
To our knowledge, no data have been gathered regarding
hERG1 channel expression in primary BC so far. Through
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Table 1: hERG1 expression and role in cell lines and in human solid tumors.
Tumor type Cell lines Human tumors
Breast cancer hERG1 current is blocked by Tamoxifen[23]; induction of cell senescence [24] —
Endometrial cancer — Overexpression [9]
Ovarian cancer Expression [13] Overexpression [13]; methylation and downregulation [25]
Esophageal cancer — Overexpression in EA and BE [11], ESCC [26]; malignantprogression [11]
Gastric cancer Cell proliferation [27]; apoptosis [28]
Grading, TNM stage, serosal, and venous invasion [29, 30];
Lauren’s intestinal type, localization (fundus), low grading, and
early stages (TNM I and II) [31]; in early stage (T1) HERG1
expression identified high-risk patients [31]
Colorectal cancer Invasiveness [10]; chemosensitivity [32];regulation of VEGF-A secretion [33]
++, correlation with invasive phenotype [10]; independent negative
prognostic factor in stage I and II CRC [34]
Pancreatic cancer Overexpression [12] Lymphnode involvement, grading, and TNM stage I [12]
Lung cancer Cell proliferation [35] —
EA: esophageal adenocarcinoma; BE: Barrett’s esophagus; ESCC: esophageal squamous cell carcinoma; TNM: tumor node metastasis; VEGF-A:vascular
endothelial growth factor.
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Figure 2: Incidence and mortality for the human solid tumors discussed in the present review. Colorectal, lung, esophageal, pancreatic, and
gastric cancers in both sexes (a) and breast, corpus uteri, and ovarian cancers in females (b). Source: GLOBOCAN 2012.
IHC experiments we demonstrated that hERG1 is overex-
pressed in primary BC and correlates with clinicopatholog-
ical parameters such as molecular subtype, grading, ER, and
ki67 expression (Lastraioli et al., submitted to Br J Cancer).
These findings might be useful in the clinical setting. It is
worth recalling here that Tamoxifen (one of the most used
drugs for BC treatment) was shown to block hERG1 currents
[23], a fact that could explain the QT interval elongation
observed in Tamoxifen-treated patients. Due to the high
expression in BC and to the sensitivity to Tamoxifen it could
be argued that hERG1 might serve as therapeutic targets
and/or predictors of response to therapy, although further
studies are surely needed.
3. Esophageal Cancer
Esophageal cancer represents the sixth leading cause of
mortality from cancer worldwide, with a 5-year mortality of
less than 15% [20, 22]. The unsatisfactory results are mainly
related to late diagnosis and complex therapeutic approaches
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that include combined regimens combining surgery (with
highmorbidity andmortality), radiotherapy, and chemother-
apy. The current curative algorithm requires perioperative
radiochemotherapy and demolitive surgery, although many
patients presenting with inoperable locoregional advanced
cancers or distant metastatic spread are proposed for pal-
liative radiochemotherapy or support therapy alone [45].
Some new molecular therapies are currently incorporated
into classical chemotherapy regimens, but results obtained
so far are not satisfactory [46]. From a histopathological
point of view, two types of cancer are the most frequent:
esophageal squamous-cell carcinoma (ESCC) and esophageal
adenocarcinoma (EA), with some differences in geographic
prevalence and risk factors [47]. A well-known precursor
lesion for EA is Barrett’s esophagus (BE). BE is a condition
where the normal squamous epithelium of the esophagus is
replaced by columnar epithelium of intestinal appearance.
BE is currently diagnosed based on the presence of goblet
cells of the intestinal type within columnar epithelium [47].
There is currently no evidence that BE screening effectively
reduces EA incidence andmortality; nevertheless in 2008 the
American Gastroenterological Association Institute recom-
mended performing screening and surveillance in patients
with chronic gastroesophageal reflux disease symptoms.
Although endoscopic surveillance might lead to early diag-
nosis, biomarkers would be more useful, as they would allow
the measurement of distinct molecular alterations within
the tissue. Among these alterations, the best characterized
is p53. The immunohistochemical detection of p53 shows
correlations with tumor progression and has been validated
in big cohorts of patients. The technical easiness of detection
makes it a promising biomarker to be translated into clinical
practice (reviewed in [48]).
The expression and prognostic role of hERG1 was inves-
tigated in ESCC by means of IHC and RT-PCR [26].
KCNH2 gene and hERG1 protein were found to be expressed
in a high percentage of ESCC samples (with respect to
normal esophageal squamous epithelium) but no correla-
tions emerged with clinicopathological features. The authors
showed that survival rates of hERG1-positive patients were
shorter than hERG1-negative patients [26].
A similar approach was applied to the study of EA
samples. In particular, the expression of hERG1 protein was
detected in BE-derived adenocarcinomas [11].
In 2006, we published the results of amulticentric study [11]
showing that hERG1 is overexpressed in the majority of BE
samples (69%)while it is absent in normal esophagealmucosa
as well as samples taken from patients affected by esophagitis.
It was also shown that hERG1 expression is switched on
at early stages of BE cancerogenesis and it is also highly
expressed in dysplasias and BE-derived adenocarcinomas,
thus characterizing both early and late steps of esophageal
cancerogenesis [11].
hERG1 channel expression also shows a significant asso-
ciationwithmalignant progression towards adenocarcinoma,
since 89% of BE patients who developed EA were positive
for hERG1 protein expression [11]. On the whole, hERG1
channels might identify high-risk BE patients and could
therefore be useful for endoscopic surveillance of BE patients
in order to ensure a better follow-up and early EA diagnosis.
4. Gastric Cancer
Gastric cancer (GC) is the third commonest cause of specific
death worldwide and 5-year survival is less than 30% [20,
21]. Many risk factors were investigated, including dietary
regimen, smoking habits, alcohol consumption, genetic pre-
disposition, andHelicobacter pylori chronic infection [48, 49].
The management of patients without distant metastases is
pivoted on surgical resection, although recent clinical trials
include perioperative chemotherapy or radiochemotherapy
especially in cancer arising from the esophagogastric junction
[48]. As many other gastrointestinal cancers, the multimodal
management is guided by a correct preoperative TNM stage
definition [45]. From a histopathological point of view,
about 90% of GCs are classified as adenocarcinomas divided
into two subtypes according to Lauren’s classification, the
intestinal and diffuse type showing different biological and
etiological characteristics.
Recently, biomolecular patterns of GC were investigated,
including E-cadherin, VEGF, and microsatellite instability
[50]. The purpose of these studies was to develop new
targeted therapies to improve the poor prognosis achieved by
standard chemotherapy. To date, the only clinical trials avail-
able are those employing Trastuzumab (with chemotherapy)
in HER2-positive advanced GC [51].
hERG1 channels have been proven to be expressed in
GC cell lines and primary GCs. In GC cell lines it was
shown that hERG1 regulates tumor proliferation [27] and that
treatment with hERG1 specific blockers and siRNA impairs
tumor growth [29, 52]. hERG1 expression was demonstrated
also in primary GCs where it correlates with grading, TNM
stage, and serosal and venous invasion [30, 31]. More recently,
through an IHC-based study in a wide cohort of GC patients
it was demonstrated that hERG1 channels are overexpressed
in gastric adenocarcinomas, especially in those of Lauren
intestinal type [31]. hERG1 expression also correlated with
grading, TNM stage, and VEGF-A expression. Moreover, in
GC cell lines it was shown that hERG1 modulates VEGF-
A secretion through an AKT-dependent pathway [31]. Even
more interestingly, by treating xenografted cancers with a
combination of hERG1 blockers and Bevacizumab the effect
was greater than that obtained with single-agent treatment
[31].
Overall, data gathered so far are still contradicting, since
Ding and colleagues proposed hERG1 as an independent
prognostic factor [30] while in our series hERG1 identi-
fies high-risk T1 patients [31] but is not an independent
prognostic factor. It should be pointed out that the cohort
analyzed in our study was bigger than the one analyzed by
Ding and colleagues and it was composed of Italian patients,
who display different characteristics than Asian patients.
Moreover, a different antibody and scoring method was
applied and this could account for differences in the obtained
results.
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In primary GC it was also demonstrated that hERG1
channels are expressed in the early stages of the disease
(manuscript in preparation and [52]). By means of IHC
we showed that hERG1 channels are expressed from the
early steps of GC progression (gastric metaplasia) and that
such expression is maintained during all the phases of the
cancerogenic process [52].
Overall, the detection of hERG1 expression in gastric dys-
plastic lesions could therefore represent a novel prognostic
marker of progression towards gastric adenocarcinoma of the
intestinal histotype.
5. Colorectal Cancer
Colorectal cancer (CRC) is the fourthmost common cause of
death for cancer worldwide, with a 5-year survival rate higher
than 60% taking into account CRC encompassing all the
pathological stages [20, 21]. The prognosis of CRC patients
has been consistently improving during the last decades due
to many important developments in prevention, early diag-
nosis, and therapy. For example, the widespread screening
colonoscopy has led to reduced cancer incidence (for benign
or preneoplastic adenomas removal) and mortality (due to
early diagnosis) [53]. TNMstaging system is highly correlated
with prognosis, with a 5-year survival of 90% for patients
in earlier stages to less than 25% for those with metastatic
disease [53]. The cornerstone of therapy is represented by en
bloc surgical resection of tumor and regional nodes, although
perioperative chemotherapy is mandatory in subjects with
advanced disease and metastasis.
The most frequent histological subtype is adenocarci-
noma, accounting for more than 95% of the cases and
the molecular pathogenesis of colorectal cancer has been
widely studied. The molecular sequence from adenoma to
invasive cancer is well established, with the identification of
misexpression and mutation of several genes (including rare
inherited syndromes). Many molecular targets are currently
used for prognostic and predictive purposes. In particular k-
ras mutation profile is used to refine prognosis and to select
patients who will benefit from treatment with anti-EGF-R
antibodies. For therapy purposes, anti-VEGF-A antibodies
have been employed in addition to standard chemotherapy
agents. Despite all the efforts, the prognosis of patients with
advanced stage disease has not been significantly improved
[54, 55].
hERG1 protein is highly expressed in colorectal adenocar-
cinomas with respect to hyperplastic lesions of the colon [11]
and in CRC cell lines [11, 33] and it was demonstrated that
the protein is not expressed in small adenomas and sigma
diverticulitis [56]. In CRC cell lines, a correlation between
invasive phenotype and high hERG1 levels of expression
has been shown [11] and proliferation assays demonstrated
that treating the cells with a specific hERG1 blocker (E4031)
reduced tumor growth [56]. The effects of a different hERG1
blocker (sparfloxacin, SPFX) were tested on colon cancer
cells with a high hERG1 expression [57]. The authors showed
that SPFX inhibits cell proliferation,migration, and apoptosis
and a synergistic effect was observed treating the cells in
combination with 5-FU [57].
In CRC cell lines it was also demonstrated that hERG1
channels modulate tumor progression by switching on a
VEGF-A-dependent angiogenic pathway [33]. hERG1 expres-
sion was also evaluated in mouse models [58]. It was
shown that colonic polyps of adenomatous polyposis coli
(Apcmin /+) mice expressed the murine homolog of hERG1
(mERG1) and that treating the animals with a specific hERG1
blocker reverted polyps development [58]. Treating trans-
genic mice (overexpressing hERG1 in the colorectal mucosa)
with a chemical carcinogen (Azoxymethane) resulted in an
increased number of mucin-depleted foci and polyps [58].
Finally, in a cohort of primary nonmetastatic CRC sam-
ples it was shown that hERG1 expression was associated with
Glut-1 (glucose transporter 1), VEGF-A, CA-IX (carbonic
anhydrase IX), and EGF-R expression [34]. In a multivariate
model, TNM, hERG1, and Glut-1 turned out to be prognostic
factors [34].Moreover, hERG1 presence associated withGlut-
1 absence represents an independent negative prognostic
factor in TNM I and II colorectal adenocarcinomas [34].
On the whole, data gathered so far in CRC cell lines,
primary CRCs, and mouse models indicate that hERG1 has
a role in CRC cancerogenesis that can be traced back to
the regulation of VEGF-A signaling pathway [33, 34, 59].
Moreover, hERG1 has a prognostic value in CRC [47] and all
these data stress the necessity of including hERG1 blocking
therapeutic strategies in CRC treatment schedules.
6. Pancreatic Cancer
Pancreatic cancer (PC) is responsible for 6.8% of all cancer-
related deaths [22]. PC incidence and mortality have been
steady in the last 20 years, and despite recent efforts to
optimize treatments, 5-year survival rate is still poor (6.7%)
[22]. Several risk factors for PC have been described. 20%
of PC is likely to be induced by cigarette smoking [21]. It
has been shown that a family history of PC also increases
the risk of developing PC [59] as well as a personal history
of chronic pancreatitis, obesity, and diabetes [21]. From a
histopathological point of view, 90% of PC is classified as
ductal adenocarcinomas (PDAC), with the other histotypes
accounting all together for the remaining 10%.
Unfortunately, currently there are no screening detection
methods and the vast majority of PC is diagnosed when the
disease has already spread beyond the pancreas. For these rea-
sons, surgery and radiochemotherapy are used as treatment
options but they can be curative only in a small percentage of
patients. For PC patients presenting with advanced disease,
chemotherapywith Erlotinib plus gemcitabine has been used,
with a slight survival improvement.
Although recently several studies have been performed
aimed at identifying novel prognostic and predictive molec-
ular biomarkers, none of them can be included in routine
clinical use yet [60].
Recently, it was demonstrated that hERG1 channels are
highly expressed in primary PC and PC cell lines [12]. In PC
samples, hERG1 expression was correlated with lymph node
6 BioMed Research International
involvement, grading, and TNM stage I [12]. The authors
also showed that hERG1 is a target of miR-96 (microRNA-
96, which is downregulated in PC) and that miR-96 over-
expression regulates hERG1 expression hence significantly
inhibiting PC cells malignant behavior.
We recently showed that hERG1 channels are overex-
pressed in human PC samples of the ductal type (PDAC)
and correlate with EGF-R [61]. Moreover, blocking hERG1
in PDAC cells reduces cell growth and migration and we
demonstrated that PDAC patients with high hERG1 expres-
sion had a worse prognosis.
7. Other Cancers
7.1. Endometrial Cancer. Endometrial cancer (EC) is nowa-
days themost commongynecologicmalignancy and themost
frequent among infiltrating tumors of the female genital tract,
especially after menopause. About 75% of the cases affect
corpus uteri and 15–20% of these show relapse and do not
respond to systemic therapy [62]. Approximately 70 to 80%
of EC patients have a localized disease that is treated by
surgery alone; nevertheless roughly 30% of the patients will
die from the disease. In this scenario, it appears clear that EC
is a heterogeneous disease and novel biomarkers are urgently
needed. This will allow better stratifying EC patients and
ensuring the best treatment options. Biomolecular research
has identified new targets for EC therapy such as mTOR
(mammalian target of rapamycin, in particular for type
I EC), p53 and HER-2 (human epidermal growth factor
receptor 2, especially in type II EC), VEGF (vascular endothe-
lial growth factor), and EGF-R (epidermal growth factor
receptor) (reviewed in [63]). A recent report summarized
data concerning new molecular markers in EC pointing out
the relevance of several markers (p53, aneuploidy, HER-2,
estrogen receptors, progesterone receptors, and Stathmin)
[64].
The first paper demonstrating the expression of hERG1
potassium channels in human primary cancers was con-
ducted on EC samples [9]. In such paper it was demonstrated
that hERG1mRNA can be detected in human tissues by end-
point RT-PCR (Retrotranscription-Polymerase Chain Reac-
tion) as well as by IHC and is more frequently expressed in
human neoplastic tissues compared to normal endometrium
and hyperplastic lesions [9]. Furthermore, patch clamp anal-
ysis indicated that functional hERG1 proteins are expressed
on the cell surface of EC cells. This paper opened the way for
further investigation of hERG1 expression in clinical samples,
although the analysis was carried out on a small group of EC
patients.
7.2. Ovarian Cancer. Ovarian cancer (OC) represents the
leading cause of death among gynecologic malignancies,
despite recent efforts in surgical and chemotherapy treat-
ments. Currently, 5-year survival for OC is 44.6% [22]. The
gold standard for OC treatment is surgery usually followed
by chemotherapy [21]. Currently, there is no screening test for
OC early detection although pelvic examination associated
with transvaginal ultrasound and CA-125 (Cancer Antigen
125) evaluation in blood samples can be proposed to high-risk
women, in particular those who have a family history positive
for BC and OC.
Several molecules have been proposed as tumor markers
forOC.Themost used serummarker is CA-125 butmany oth-
ers have been tested as well (such as HE4 (human epididymal
protein E4), Kallikreins, Osteopontin, Claudins, and VCAM-
1 (vascular cell adhesion molecule 1)) (reviewed by [65]).
Among epigenetic aberrations thatmight be used as biomark-
ers, the best characterized is BRCA1 hypermethylation which
leads to the absence ofmRNA and protein and correlates with
poor outcome [66]. Since VEGF-A and VEGFR-2 (vascular
endothelial growth factor receptor 2) expression might be
associated with reduced survival, a phase III clinical trial
employing Bevacizumab in recurrent platinum-resistant OC
patients (AURELIA Trial) was designed and such treatment
resulted in a significant improvement of PFS (progression-
free survival) and ORR (objective response rate) [67].
On the whole, despite the wide spectrum of serum
biomarkers identified, unsatisfactory clinical results have
been achieved. For these reasons, search for new biomarkers
is mandatory.
A few studies have been performed to evaluate hERG1
expression and role in OC. A paper published in 2010 [13]
demonstrated that hERG1 is expressed in OC cell lines and
primary samples but no associations with survival emerged.
More recently, a methylation profile for clear-cell OC was
defined [25]. Among the nine genes investigated the authors
included hERG1 potassium channel and they showed that
the gene was methylated and hence its expression in the
tumor tissue was lower, indicating epigenetic silencing.Those
results, although obtained in a small set of OC samples, might
indicate that that loss of hERG1 expression by methylation
could represent a potential prognostic marker.
8. Concluding Remarks
Despite the improvements in surgical techniques and
chemotherapy schedules, the treatment of solid cancers is
still a big challenge for surgeons and oncologists. Therefore,
targeted therapy represents the best opportunity for the treat-
ment of patients not responding to classical approaches. Data
gathered so far suggest that hERG1 channels could be used as
biomarkers since they are frequently overexpressed in solid
cancers and such expression associates with clinicopatho-
logical features in different tumors. A reliable monoclonal
antibody for hERG1 protein is available and evaluation scores
have been optimized in different solid cancer, thus making
the detection of the channel easy for pathologists. Moreover,
being a transmembrane protein, hERG1 is easily accessible
and might be targeted by several small molecules that might
be associated with the treatment with drugs already used in
the clinical settings, contributing to lower costs of cancer
patients’ treatment. Moreover, anti-hERG1 antibody and its
derivative scFv (Single Chain Variable Fragment) might be
conjugated with drugs for treatment. Different strategies
might be applied such as targeting specific conformations
of hERG1 channels and using new molecular tools aimed at
BioMed Research International 7
decreasing hERG1 expression in tumor cells only to decrease
channel expression in selected cancer types (for a more
detailed review see [19, 68]).
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